Drug Trial Radar · NCT05627648
Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Dec 1, 2022
Primary completion
Jul 31, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Kringle Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the efficacy and safety of KP-100LI, a intracordal formulation containing recombinant human dHGF as the active pharmaceutical ingredient, for voice function improvement therapy in patients with vocal fold scar (including vocal fold sulcus).
Conditions
- Vocal Fold Scar
Interventions
KP-100LIDrug
Intracordal injection, 20 mcg once per week, 3 weeks
PlaceboDrug
Intracordal injection, once per week, 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement rate in Voice Handicap Index-10 (VHI-10) score at 24 weeks of the observational periodTime frame: 24 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
Fukuoka Sanno Hospital
Fukuoka, Fukuoka, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
University Hospital Kyoto Prefectural University of Medicine
Kamigyō-ku, Kyoto, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Kawasaki Medical School Hospital
Kurashiki, Okayama-ken, Japan
Nihon University Hospital
Chiyoda-ku, Tokyo, Japan
Sanno Medical Center
Minato-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.